“Soft Tissue Sarcoma Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Soft Tissue Sarcoma market. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided, which includes the disease overview and Soft Tissue Sarcoma treatment guidelines.
The assessment part of the report embraces in-depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the Soft Tissue Sarcoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The launch of the emerging therapies is expected to significantly impact Soft Tissue Sarcoma treatment scenario in the upcoming years:-
Drugs covered1. Avapritinib (BLU-285)2. Anlotinib (AL3818)3. Selinexor4. Aldoxorubicin (INNO-206)5. Ripretinib (DCC-2618)6. Fibromun (In combination with Doxorubicin)7. Hensify (NBTXR3)8. Crenolanib9. TAS-11610. GSK337779411. ADP-A2M412. Tazemetostat (EPZ-6438)13. AMG 33714. GB226/APL-50115. CamsirubicinAnd many others
The key players in Soft Tissue Sarcoma market are:1. Blueprint Medicines Corporation2. Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical3. Karyopharm Therapeutics4. Deciphera Pharmaceuticals5. Philogen6. GlaxoSmithKline7. Epizyme8. Eli Lilly and Company9. Pfizer10. Aadi Bioscience11. Sierra Oncology12. Nanobiotix13. Taiho Oncology14. Arog Pharmaceuticals15. Merck Sharp & DohmeAnd many others
Request for sample pages: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight
Table of contents:
1. Report Introduction
2. Soft Tissue Sarcoma
2.1. Overview
2.2. History
2.3. Soft Tissue Sarcoma Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Soft Tissue Sarcoma Diagnosis
2.6.1. Diagnostic Guidelines
3. Soft Tissue Sarcoma Current Treatment Patterns
3.1. Soft Tissue Sarcoma Treatment Guidelines
4. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Soft Tissue Sarcoma companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Soft Tissue Sarcoma Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Soft Tissue Sarcoma Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Soft Tissue Sarcoma Late Stage Products (Phase-III)
7. Soft Tissue Sarcoma Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Soft Tissue Sarcoma Discontinued Products
13. Soft Tissue Sarcoma Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Soft Tissue Sarcoma Key Companies
15. Soft Tissue Sarcoma Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Soft Tissue Sarcoma Unmet Needs
18. Soft Tissue Sarcoma Future Perspectives
19. Soft Tissue Sarcoma Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/